{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:24:00Z","timestamp":1791181440105,"version":"4.1.0"},"reference-count":23,"publisher":"American Society of Hematology","issue":"13","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2014,9,25]]},"abstract":"<jats:title>Key Points<\/jats:title>\n               <jats:p>In ET, a CALR mutation correlates with a monoclonal X chromosome inactivation pattern, which differs from JAK2V617F mutant disease. The presence of a CALR mutant is associated with suppression of wild-type myelopoiesis.<\/jats:p>","DOI":"10.1182\/blood-2014-06-580183","type":"journal-article","created":{"date-parts":[[2014,8,20]],"date-time":"2014-08-20T05:39:15Z","timestamp":1408513155000},"page":"2091-2093","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["X chromosome inactivation analysis reveals a difference in the biology of ET patients with JAK2 and CALR mutations"],"prefix":"10.1182","volume":"124","author":[{"given":"Christopher","family":"Allen","sequence":"first","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan R.","family":"Lambert","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Linch","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosemary E.","family":"Gale","sequence":"additional","affiliation":[{"name":"Department of Haematology, University College London Cancer Institute, London, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"1","key":"2019111817343252500_B1","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood.V89.1.128","article-title":"Clonality analysis of hematopoiesis in essential thrombocythemia: advantages of studying T lymphocytes and platelets.","volume":"89","author":"el-Kassar","year":"1997","journal-title":"Blood"},{"issue":"2","key":"2019111817343252500_B2","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1182\/blood.V93.2.417.402a33_417_424","article-title":"A large proportion of patients with a diagnosis of essential thrombocythemia do not have a clonal disorder and may be at lower risk of thrombotic complications.","volume":"93","author":"Harrison","year":"1999","journal-title":"Blood"},{"issue":"6","key":"2019111817343252500_B3","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1016\/S0301-472X(01)00640-3","article-title":"Clonal hemopoiesis and risk of thrombosis in young female patients with essential thrombocythemia.","volume":"29","author":"Chiusolo","year":"2001","journal-title":"Exp Hematol"},{"issue":"5","key":"2019111817343252500_B4","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1182\/blood.V100.5.1596.h81702001596_1596_1601","article-title":"Predictive values of X-chromosome inactivation patterns and clinicohematologic parameters for vascular complications in female patients with essential thrombocythemia.","volume":"100","author":"Shih","year":"2002","journal-title":"Blood"},{"issue":"10","key":"2019111817343252500_B5","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1038\/sj.leu.2403902","article-title":"Clinical implications of the JAK2 V617F mutation in essential thrombocythemia.","volume":"19","author":"Antonioli","year":"2005","journal-title":"Leukemia"},{"issue":"10","key":"2019111817343252500_B6","doi-asserted-by":"crossref","first-page":"4139","DOI":"10.1182\/blood-2005-09-3900","article-title":"X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET\/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis.","volume":"107","author":"Levine","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111817343252500_B7","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1038\/sj.leu.2404214","article-title":"Essential thrombocythemias without V617F JAK2 mutation are clonal hematopoietic stem cell disorders.","volume":"20","author":"Kiladjian","year":"2006","journal-title":"Leukemia"},{"issue":"4","key":"2019111817343252500_B8","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1182\/blood-2005-11-009605","article-title":"Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders.","volume":"108","author":"Kralovics","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111817343252500_B9","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1182\/blood-2006-01-013540","article-title":"The JAK2-V617F mutation is frequently present at diagnosis in patients with essential thrombocythemia and polycythemia vera.","volume":"108","author":"Lippert","year":"2006","journal-title":"Blood"},{"issue":"3","key":"2019111817343252500_B10","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1182\/blood-2006-06-029769","article-title":"Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years.","volume":"109","author":"Gale","year":"2007","journal-title":"Blood"},{"issue":"11","key":"2019111817343252500_B11","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.3324\/haematol.13081","article-title":"Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy.","volume":"93","author":"Girodon","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2019111817343252500_B12","doi-asserted-by":"crossref","first-page":"1890","DOI":"10.3324\/haematol.13074","article-title":"The allele burden of JAK2 mutations remains stable over several years in patients with myeloproliferative disorders.","volume":"93","author":"Theocharides","year":"2008","journal-title":"Haematologica"},{"issue":"8","key":"2019111817343252500_B13","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.3324\/haematol.2009.021444","article-title":"Hydroxyurea does not appreciably reduce JAK2 V617F allele burden in patients with polycythemia vera or essential thrombocythemia.","volume":"95","author":"Antonioli","year":"2010","journal-title":"Haematologica"},{"issue":"10","key":"2019111817343252500_B14","doi-asserted-by":"crossref","first-page":"3472","DOI":"10.1182\/blood-2006-04-018879","article-title":"MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.","volume":"108","author":"Pardanani","year":"2006","journal-title":"Blood"},{"issue":"1","key":"2019111817343252500_B15","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","article-title":"MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort.","volume":"112","author":"Beer","year":"2008","journal-title":"Blood"},{"issue":"25","key":"2019111817343252500_B16","doi-asserted-by":"crossref","first-page":"2379","DOI":"10.1056\/NEJMoa1311347","article-title":"Somatic mutations of calreticulin in myeloproliferative neoplasms.","volume":"369","author":"Klampfl","year":"2013","journal-title":"N Engl J Med"},{"issue":"25","key":"2019111817343252500_B17","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1056\/NEJMoa1312542","article-title":"Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.","volume":"369","author":"Nangalia","year":"2013","journal-title":"N Engl J Med"},{"issue":"10","key":"2019111817343252500_B18","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1182\/blood-2013-11-539098","article-title":"JAK2 or CALR mutation status defines subtypes of essential thrombocythemia with substantially different clinical course and outcomes.","volume":"123","author":"Rumi","year":"2014","journal-title":"Blood"},{"issue":"10","key":"2019111817343252500_B19","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1182\/blood-2013-11-538983","article-title":"Impact of calreticulin mutations on clinical and hematological phenotype and outcome in essential thrombocythemia.","volume":"123","author":"Rotunno","year":"2014","journal-title":"Blood"},{"issue":"4","key":"2019111817343252500_B20","first-page":"361","article-title":"Evaluation of clonality in myeloid stem-cell disorders.","volume":"36","author":"Gale","year":"1999","journal-title":"Semin Hematol"},{"issue":"6","key":"2019111817343252500_B21","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1111\/j.1365-2141.2008.07560.x","article-title":"Clonal diversity in the myeloproliferative neoplasms: independent origins of genetically distinct clones.","volume":"144","author":"Beer","year":"2009","journal-title":"Br J Haematol"},{"issue":"14","key":"2019111817343252500_B22","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","article-title":"Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms.","volume":"123","author":"Lundberg","year":"2014","journal-title":"Blood"},{"key":"2019111817343252500_B23","article-title":"Calreticulin mutation-specific immunostaining in myeloproliferative neoplasms: pathogenetic insight and diagnostic value [published online ahead of print March 12, 2014].","author":"Vannucchi","journal-title":"Leukemia"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/13\/2091\/1379558\/2091.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/124\/13\/2091\/1379558\/2091.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T22:34:44Z","timestamp":1574116484000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/124\/13\/2091\/33058\/X-chromosome-inactivation-analysis-reveals-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,9,25]]},"references-count":23,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,9,25]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2014-06-580183","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,9,25]]}}}